Cellosaurus logo
expasy logo

Cellosaurus HCC827 GR1 (CVCL_V620)

[Text version]
Cell line name HCC827 GR1
Accession CVCL_V620
Resource Identification Initiative To cite this cell line use: HCC827 GR1 (RRID:CVCL_V620)
Comments Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Iressa).
Derived from site: In situ; Lung; UBERON=UBERON_0002048.
Sequence variations
  • Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line).
Disease Lung adenocarcinoma (NCIt: C3512)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_2063 (HCC827)
Sex of cell Female
Age at sampling 39Y
Category Cancer cell line
Publications

PubMed=17463250; DOI=10.1126/science.1141478
Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N.I., Gale C.-M., Zhao X.-J., Christensen J.G., Kosaka T., Holmes A.J., Rogers A.M., Cappuzzo F., Mok T., Lee C., Johnson B.E., Cantley L.C., Janne P.A.
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Science 316:1039-1043(2007)

Cross-references
Cell line databases/resources cancercelllines; CVCL_V620
Encyclopedic resources Wikidata; Q54881788
Gene expression databases GEO; GSM466320
Polymorphism and mutation databases Progenetix; CVCL_V620
Entry history
Entry creation16-Apr-2014
Last entry update05-Oct-2023
Version number15